Table 1. Descriptive statistics by mortality status at the end of follow-up.

	Deceased at the End of Follow-up
List of Variables	No	Yes	p-value
	N = 3044	N = 499
Programmatic Compliance Score
0	565 (98%)	13 (2%)	<0.0001
1	868 (93%)	68 (7%)
2	845 (88%)	111 (12%)
3	449 (80%)	114 (20%)
4 or more	317 (62%)	193 (38%)
Age
Median	41	44	<0.0001
Q1–Q3	35–48	37–51
Follow-up (in months)
Median	47	23	<0.0001
Q1–Q3	25–82	6–48
Gender
Male	2431 (86%)	385 (14%)	0.1692
Female	613 (84%)	114 (16%)
Injection drug use history
No	1918 (89%)	248 (11%)	<0.0001
Yes	1126 (82%)	251 (18%)
Adherence during first year
≥95%	2008 (90%)	216 (10%)	<0.0001
<95%	1036 (78%)	283 (21%)
Year of first ARV
2000–2005	1455 (79%)	381 (21%)	<0.0001
2006–2010	1589 (93%)	118 (7%)
Number of CD4 cell count measurements (1st year)
≥3	2412 (89%)	309 (11%)	<0.0001
<3	632 (77%)	190 (23%)
Number of plasma HIV-1 RNA level measurements (1st year)
≥3	2665 (90%)	303 (10%)	<0.0001
<3	379 (66%)	196 (34%)
Baseline resistance test
Yes	1871 (91%)	184 (9%)	<0.0001
No	1173 (79%)	315 (21%)
Baseline CD4 cell count (cells/mm3)
≥200	1535 (91%)	157 (9%)	<0.0001
<200	1509 (81%)	342 (18%)
Recommended HAART regimen
Yes	2718 (87%)	422 (13%)	<0.0001
No	326 (81%)	77 (19%)
Suppression at 6 month
Yes	1789 (93%)	127 (7%)	<0.0001
No	1255 (77%)	372 (23%)
Health Region
Vancouver Coastal HA - City Center	1961 (88%)	273 (12%)	<0.0001
Vancouver Coastal HA - DTES	196 (78%)	55 (22%)
Vancouver Coastal HA - Other	265 (90%)	31 (10%)
Interior HA	118 (83%)	25 (17%)
Fraser HA	170 (80%)	42 (20%)
Vancouver Island HA	266 (82%)	60 (18%)
Northern HA	68 (84%)	13 (16%)

Notes: HA: Health Authority, Q1: 25th percentile; Q3: 75th percentile.